This article has Open Peer Review reports available.
Higher anti-depressant dose and major adverse outcomes in moderate chronic kidney disease: a retrospective population-based study
© Dev et al.; licensee BioMed Central Ltd. 2014
Received: 6 January 2014
Accepted: 1 May 2014
Published: 10 May 2014
Many older patients have chronic kidney disease (CKD), and a lower dose of anti-depressants paroxetine, mirtazapine and venlafaxine is recommended in patients with CKD to prevent drug accumulation from reduced elimination. Using information available in large population-based healthcare administrative databases, we conducted this study to determine if ignoring the recommendation and prescribing a higher versus lower dose of anti-depressants associates with a higher risk of adverse events.
We conducted a population-based cohort study to describe the 30-day risk of delirium in older adults who initiated a higher vs. lower dose of these three anti-depressants in routine care. We defined delirium using the best proxy available in our data sources - hospitalization with an urgent head computed tomography (CT) scan. We determined if CKD status modified the association between anti-depressant dose and outcome, and examined the secondary outcome of 30 day all-cause mortality. We used multivariable logistic regression analyses to estimate adjusted odds ratios (relative risk (RR)) and 95% confidence intervals.
We identified adults (mean age 75) in Ontario who started a new study anti-depressant at a higher dose (n = 36,651; 31%) or lower dose (n = 81,160; 69%). Initiating a higher vs. lower dose was not associated with an increased risk of hospitalization with head CT (1.09% vs. 1.27% (adjusted RR 0.90; 95% CI, 0.80 to 1.02), but was associated with a lower risk of all-cause mortality (0.76% vs. 0.97% RR 0.82; 95% CI, 0.71 to 0.95). Neither of these relative risks were modified by the presence of CKD (p = 0.16, 0.68, respectively).
We did not observe an increase in two adverse outcomes when study anti-depressants were initiated at a higher dose in elderly patients with moderate CKD. Contrary to our hypothesis, the 30-day risk of mortality was lower when a higher versus lower dose of anti-depressant was initiated in these patients, a finding which requires corroboration and further study.
KeywordsAnti-depressant Delirium Aged Chronic renal insufficiency Cohort studies Risk
Anti-depressant dosing in popular drug prescribing references
Higher dose (mg/day)*
Lower dose (mg/day)*
Systematic review ]
• 20 – 50 mg/day
• 20 – 50 mg/day
• 20 – 50 mg/day
• Reduce by 50% with CrCl < 30 ml/min
• Initiate at 10 mg/day with CrCl < 40 ml/min
• Initiate at 10 mg/day with eGFR < 60 ml/min
• 15 – 45 mg/day
• 15 – 45 mg/day
• 15 – 45 mg/day
• Use with caution with CrCl < 40 ml/min
• Use with caution
• Use with caution
• Initiate at 15 mg/day with eGFR < 30 ml/min
• 75 – 225 mg/day
• 75 – 225 mg/day
• 75 – 225 mg/day
• Reduce by 25 – 50% with CrCl 10 – 70 ml/min
• Reduce by 25 – 50% with GFR 10–70 ml/min
• Reduce to 37.5 mg/day with eGFR < 30 ml/min
• Initiate at 37.5 mg/day
Setting and study design
Residents of the province of Ontario, Canada have universal access to hospital care and physician services. Those 65 years of age or older, representing approximately 2 million individuals in 2012, also have universal prescription coverage . All health care encounters in Ontario are recorded in linked, de-identified databases at the Institute for Clinical Evaluative Sciences (ICES). We conducted a retrospective, population-based cohort study using six of these healthcare databases. We conducted this study according to a pre-specified protocol that was approved by the research ethics board at Sunnybrook Health Sciences Centre (Toronto, Canada). The reporting of this study follows guidelines for observational studies (detailed in Additional file 1: Figure S1) .
We ascertained baseline characteristics, drug use and dose, and outcome data using six linked healthcare databases. Demographic and vital status information on all Ontario residents who have ever been issued a health card is recorded in the Ontario Registered Persons Database (RPDB). Detailed diagnostic and procedural information on all hospital admissions and emergency room visits is recorded in the Canadian Institute for Health Information Discharge Abstract Database (CIHI-DAD) and the National Ambulatory Care Reporting System (NACRS), respectively. Health claims for inpatient and outpatient physician services are recorded in the Ontario Health Insurance Plan database (OHIP). Outpatient prescription drug information including the dispensing date, quantity of pills, dose, and number of days supplied is accurately recorded in the Ontario Drug Benefit Program database (ODB), with an error rate less than 1% . Lastly, the ICES Physician Database (IPDB) contains information on all physicians in Ontario such as sub-specialty, education, location and demographics.
Among a subpopulation of patients with prescriptions filled in Southwestern Ontario, we also obtained baseline serum creatinine values from two linked laboratory datasets: Gamma-Dynacare, a large outpatient provincial laboratory provider and Cerner® (Kansas City, Missouri, USA), an electronic medical record database containing inpatient, outpatient, and emergency department laboratory values for 12 hospitals in Southwestern Ontario . The most recent serum creatinine was obtained in the year prior to the study anti-depressant prescription (median 94 days prior to the prescription). These data sources have been used previously to study drug safety [29–31]. With the exception of anti-depressant prescriber specialty and income quintile (missing in 13.5% and 0.3% of patients, respectively), the databases were complete for all variables used in this study.
We established a cohort of all older adults in Ontario who had evidence of a new outpatient prescription for a study anti-depressant (defined as no prescriptions for any type of study or non-study anti-depressant in the prior six months) between April 1st, 2002 and December 31st 2011 (n = 169,435). The three study anti-depressants were paroxetine, mirtazapine, and venlafaxine. Patients with multiple eligible prescriptions could only enter the cohort once, and the date of anti-depressant initiation served as the patient’s index date (cohort entry date; start of follow-up). We assessed baseline demographic characteristics, co-morbid conditions (5 years prior to index date) and concurrent drug therapy (180 days prior to index date) among all individuals. We excluded the following anti-depressant users from the analysis: those in the first year of eligibility for prescription drug coverage (age 65 years) to avoid incomplete medication records (n = 12,588); those who were discharged from hospital in the two days before their index date to ensure that prescriptions were new outpatient anti-depressant prescriptions (as in Ontario, patients continuing an antidepressant treatment initiated in hospital would have their oral outpatient antidepressant prescription dispensed on the same day or the day after hospital discharge) (n = 3,833); those living in long-term care facilities because some residents chronically experience bouts of confusion (n = 30,360); those with end-stage renal disease since treatments such as dialysis alter anti-depressant pharmacokinetics unpredictably  (n = 1,522); and those who received more than one type of anti-depressant on their index date to allow comparison of mutually exclusive exposure groups (n = 3,321). A total of 117,811 patients were included in the final analysis.
We identified individuals with moderate CKD using an algorithm of diagnosis codes validated in our region for older adults . The algorithm identifies a group of patients with a low GFR by the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula. It identified patients with a median estimated glomerular filtration rate (eGFR) of 38 mL/min per 1.73 m2 (interquartile range 27 to 52), whereas its absence identified patients with a median eGFR of 69 mL/min per 1.73 m2 (interquartile range 56 to 82).
To align with recommendations in drug prescribing references, a higher dose of anti-depressant was defined as > 20 mg/day of paroxetine, > 20 mg/day of mirtazapine, or > 37.5 mg/day of venlafaxine (Table 1). A lower dose of anti-depressant was defined as ≤ 20 mg/ day of paroxetine, ≤ 20 mg/day of mirtazapine, or ≤ 37.5 mg/day of venlafaxine (Table 1).
As most reported anti-depressant related delirium occurs within the first few weeks of drug initiation, we followed all individuals for 30 days after first anti-depressant use for two pre-specified outcomes . Our primary outcome was hospitalization with evidence of an urgent head CT scan. We used this as a proxy for the presence of acute central nervous system disturbance (i.e. delirium), as many patients in Ontario undergo such diagnostic imaging when presenting to hospital with acute confusion. Unlike diagnostic codes for acute delirium, the receipt of a head CT scan is well coded in our data sources because they are associated with physician reimbursement . To focus on urgent imaging conducted for acute reasons at the time of hospital admission, we only considered head CT scans performed in the first five days of a hospital admission, or in the emergency department assessment preceding the hospital admission. We expected urgent head CT scans conducted for reasons unrelated to anti-depressant dosing (e.g. stroke, headache) to occur at a similar frequency in higher and lower dose groups, not impacting estimates of difference in risk between the two groups. Our secondary outcome was all-cause mortality which is well coded in our data sources .
We compared baseline characteristics between those prescribed higher vs. lower daily doses of study anti-depressants using standardized differences. This metric describes differences between group means relative to the pooled standard deviation and indicates a meaningful difference if greater than 10% . We used multivariable logistic regression analyses (PROC LOGISTIC; SAS Institute, Cary, North Carolina) to estimate adjusted odds ratios and 95% confidence intervals. We adjusted for 15 potential confounders: antidepressant type, age, sex, year of cohort entry, modified Charlson score (a co-morbidity index), and concurrent medication use (anticonvulsants, gabapentin, antipsychotics, barbiturates, benzodiazepines, histamine2-receptor antagonists, dopamine agonists, muscle relaxants, opioids and overactive bladder medications). Outcomes are expressed with patients receiving a lower dose of anti-depressant as the referent group. We then tested for statistical interactions to determine whether the association between anti-depressant drug dose (higher vs. lower) and outcome was modified by the presence of moderate CKD. All odds ratios were interpreted as relative risks (appropriate given the low incidences observed). We conducted all statistical analyses using SAS, version 9.3.
Baseline characteristics by anti-depressant dose
N = 36,651
N = 81,160
Anti-depressant type, n (%)
Age, years, mean (SD)
Women, n (%)
Year of cohort entry, n (%)
Income quintile, n (%)
Rural Location, n (%)
Modified Charlson score Ŧ , n (%)
0 or no hospitalization
Co-morbidities £ , n (%)
Chronic liver disease
Chronic kidney disease*
Chronic obstructive pulmonary disease
Coronary artery disease¶
Stroke/Transient ischemic attack
Diabetes mellitus (on medication)+
Medication ¥ , n (%)
Overactive bladder medications
Prescribing physician, n (%)
30-day hospitalization with urgent head Computed Tomography (CT) scan
Association between anti-depressant dose and 30-day outcomes
Number of events, n (%)
Relative risk (Unadjusted)
Relative risk (Adjusted)
Absolute risk reduction (%)
N = 36,651
N = 81,160
Hospital admission with head CT scan
0.86 (0.76 – 0.96)
0.90 (0.80 – 1.02)
0.78 (0.68 – 0.89)
0.82 (0.71 – 0.95)
0.22 (0.10 – 0.33)
30-day all-cause mortality
Initiation of a higher vs. lower anti-depressant dose was associated with a lower risk of 30-day all-cause mortality (Table 3; 278/36,651 [0.76%] vs. 791/81,160 [0.97%], absolute risk reduction 0.22% [95% CI 0.10% to 0.33%], unadjusted relative risk 0.78 [95% CI 0.68 to 0.89]). Adjusting for 15 potential confounders had no appreciable impact on this observed association (adjusted relative risk 0.82 [95% CI 0.71 to 0.95; Table 3). The association was not appreciably different in patients with and without moderate CKD (when the presence of this condition was assessed with diagnosis codes; Figure 1; interaction P value = 0.96). The association was also not appreciably different in patients with and without moderate CKD when examined separately by each of the three anti-depressant drugs (Figure 2).
In the primary cohort we considered the outcome of hospitalization using diagnostic codes for delirium (recognizing the coding for this outcome is insensitive and underestimates events but was expected not to operate differently in the two anti-depressant dose groups). Initiation of a higher vs. lower anti-depressant dose was not associated with a difference in risk of hospitalization with delirium (43/36,651 [0.16%] vs. 126/81,160 [0.12%], unadjusted relative risk 0.76 [95% CI 0.53 to 1.07]). The association was not different in patients with and without moderate CKD (interaction P value = 0.75).
We report the 30-day risk of two major adverse events as assessed in large healthcare administrative databases in older adults who initiated a higher vs. lower dose of one of three common anti-depressants used in routine outpatient care. Contrary to our expectation, compared to a lower dose, initiation of a higher dose of anti-depressant was associated with a lower 30-day risk of all-cause mortality. This association appeared similar in patients with and without moderate CKD, although estimates in patients with CKD were less precise. There was no association between the anti-depressant dose and the risk of hospitalization with urgent neuroimaging, an extreme outcome in the spectrum of delirium.
It is well established that older individuals are more prone to adverse drug reactions [8, 9, 33]. We hypothesized that the presence of moderate CKD would make older adults particularly vulnerable to toxicity from higher doses of three study anti-depressants that have been shown to accumulate in CKD (paroxetine, mirtazapine, venlafaxine). The data supporting dose reductions of these anti-depressants comes from pharmacokinetic studies and case studies [6, 12]. To our knowledge, our study is the first to examine the clinical consequences of failing to dose adjust anti-depressants in the setting of moderate CKD at the population level. There is a need to determine if drug dosing decisions based on pharmacokinetic data influence real practice outcomes. The lower risk of death we observed with higher doses of anti-depressant was contrary to our hypothesis. It is possible the association relates to unmeasured confounding between the two dosing groups. It is also possible that higher vs. lower doses of anti-depressants are more efficacious in treating depression and improve survival. Inadequately treated depression can increase mortality risk through nonadherence to medications and health care appointments, poor nutrition, lack of social support, increased inflammation and compromised immunity [37–40]. Examining the causes of death such as suicide or withdrawal of care in this context would be useful in future studies, as such information was not reliable in our data sources.
With respect to patient safety, if concerns remain about the use of certain anti-depressants in patients with moderate CKD, a reasonable alternative is to prescribe an anti-depressant such as fluoxetine where the pharmacokinetics are not altered by the presence of CKD. Observational data also suggests that this anti-depressant is well tolerated by patients with CKD .
Our study has several strengths. The use of Ontario’s broadly inclusive healthcare databases provided us with a large representative sample. The data was complete, drug dose and outcomes were accurately recorded, and patient loss to follow-up was minimal (emigration in our region is less than 1% per year) .
Our study has several limitations. The similarity of measured patient baseline characteristics in our two anti-depressant dose groups helped reduced concerns about the influence of confounding. The concern over residual confounding was also reduced by the lack of substantial change in the observed association after adjustment for multiple potential confounders. However, as mentioned, as in any observational study the possibility of unmeasured confounding can never be completely eliminated. We knew the anti-depressant was dispensed by a pharmacy but had no information on compliance. Future studies should include more patients with very low levels of eGFR (i.e. < 30 mL/min per 1.73 m2), and should also collect body weight so that eGFR can also be expressed in mL/min. Our primary outcome was assessed retrospectively using existing healthcare database records and relied on urgent neuroimaging as a proxy for the diagnosis of delirium, which is an insensitive method to identify important changes in cognition. Rather, if resources allow for it, a well-designed prospective study with independent outcome adjudication would more precisely capture benefits and risks associated with initiating a higher vs. lower anti-depressant dose.
In this study which used large healthcare administrative databases, contrary to our hypothesis we failed to observe an association between initiation of a study anti-depressant at a higher dose and a higher risk of two adverse outcomes in older adults with moderate CKD.
We thank Brogan Inc, Ottawa, for use of its Drug Product and Therapeutic Class Database, Gamma Dynacare for use of the outpatient laboratory database and the team at London Health Sciences Centre, St. Joseph’s Health Care, and the Thames Valley Hospitals for providing access to the Cerner laboratory database. We thank Ms. Lihua Li for her help with the graphs and members of the provincial ICES Kidney Dialysis and Transplantation Program (http://www.ices.on.ca) for their support of this study.
- Wiese BS: Geriatric depression: The use of antidepressants in the ederly. BC Med J. 2011, 53 (7): 341-347.Google Scholar
- Gunnell D, Ashby D: Antidepressants and suicide: what is the balance of benefit and harm. BMJ (Clinical research ed). 2004, 329 (7456): 34-38. 10.1136/bmj.329.7456.34. doi:10.1136/bmj.329.7456.34View ArticleGoogle Scholar
- Exeter D, Robinson E, Wheeler A: Antidepressant dispensing trends in New Zealand between 2004 and 2007. Aust N Z J Psychiatry. 2009, 43 (12): 1131-1140. 10.3109/00048670903279879. doi:10.3109/00048670903279879View ArticlePubMedGoogle Scholar
- Moore M, Yuen HM, Dunn N, Mullee MA, Maskell J, Kendrick T: Explaining the rise in antidepressant prescribing: a descriptive study using the general practice research database. BMJ. 2009, 339 (b39999): doi:10.1136/bmj.b3999Google Scholar
- Austin PC, Ph D, Upshur REG, Sc M: Use of Antidepressants Among Elderly Subjects: Trends and Contributing Factors. Am J Psychiatry. 2000, 157: 360-367. 10.1176/appi.ajp.157.3.360.View ArticlePubMedGoogle Scholar
- Nagler EV, Webster AC, Vanholder R, Zoccali C: Antidepressants for depression in stage 3–5 chronic kidney disease: a systematic review of pharmacokinetics, efficacy and safety with recommendations by European Renal Best Practice (ERBP). Nephrol Dial Transplant. 2012, 27 (10): 3736-3745. 10.1093/ndt/gfs295. doi:10.1093/ndt/gfs295View ArticlePubMedGoogle Scholar
- Smith GC, Clarke DM, Handrinos D, Trauer T: Adverse reactions to antidepressants in consultation-liaison psychiatry inpatients. Psychosomatics. 2002, 43 (3): 228-33. 10.1176/appi.psy.43.3.228. doi:10.1176/appi.psy.43.3.228View ArticlePubMedGoogle Scholar
- Dormann H, Sonst A, Müller F, Vogler R, Patapovas A, Pfistermeister B, Plank-Kiegele B, Kirchner M, Hartmann N, Bürkle T, Maas R: Adverse drug events in older patients admitted as an emergency: the role of potentially inappropriate medication in elderly people (PRISCUS). Dtsch Arztebl Int. 2013, 110 (13): 213-9. doi:10.3238/arztebl.2013.0213PubMedPubMed CentralGoogle Scholar
- Routledge PA, O’Mahony MS, Woodhouse KW: Adverse drug reactions in elderly patients. Br J Clin Pharmacol. 2003, 57 (2): 121-126. 10.1046/j.1365-2125.2003.01875.x. doi:10.1046/j.1365-2125.2003.01875.xView ArticleGoogle Scholar
- Group, KDIGO (KDIGO) CW: KDIGO: Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int Suppl. 2012, 2013 (3): 1-150.Google Scholar
- Schaeffner ES, Ebert N, Delanaye P, Frei U, Gaedeke J, Jakob O, Kuhlmann MK, Schuchardt M, Tolle M, Ziebig R, van der Giet M, Martus P: Two novel equations to estimate kidney function in persons aged 70 years or older. Ann Intern Med. 2013, 157 (7): 471-481.View ArticleGoogle Scholar
- Cohen LM, Tessier EG, Germain MJ, Levy NB: Update on psychotropic medication use in renal disease. Psychosomatics. 2004, 45 (1): 34-48. 10.1176/appi.psy.45.1.34. doi:10.1176/appi.psy.45.1.34View ArticlePubMedGoogle Scholar
- Crone CC, Gabriel GM: Treatment of anxiety and depression pharmacokinetic considerations. Clin Pharmacokinet. 2004, 43 (6): 361-394. 10.2165/00003088-200443060-00002.View ArticlePubMedGoogle Scholar
- Baghdady NT, Banik S, Swartz SA, McIntyre RS: Psychotropic drugs and renal failure: translating the evidence for clinical practice. Adv Ther. 2009, 26 (4): 404-424. 10.1007/s12325-009-0021-x. doi:10.1007/s12325-009-0021-xView ArticlePubMedGoogle Scholar
- Bailer U, Fischer P, Küfferle B, Stastny J, Kasper S: Occurrence of mirtazapine-induced delirium in organic brain disorder. Int Clin Psychopharmacol. 2000, 15 (4): 239-243. 10.1097/00004850-200015040-00009. Available at: http://www.ncbi.nlm.nih.gov/pubmed/10954066 View ArticlePubMedGoogle Scholar
- Alexander J, Nillsen A: Venlafaxine-induced delirium. Aust N Z J Psychiatry. 2011, 45 (7): 606-doi:10.3109/00048674.2011.567968View ArticlePubMedGoogle Scholar
- Chuang Y-F, Chiu Y-L, Hwang T-J, Chu T-S: Delirium and multiple electrolyte abnormalities associated with high dose paroxetine exposure. Psychiatry Clin Neurosci. 2006, 60 (5): 642-643. 10.1111/j.1440-1819.2006.01574.x. doi:10.1111/j.1440-1819.2006.01574.xView ArticlePubMedGoogle Scholar
- Wakeno M, Okugawa G, Takekita Y, Kato M, Fukuda T, Yamashita M, Hosoi Y, Azuma J: Delirium associated with paroxetine in an elderly depressive patient: a case report. Pharmacopsychiatry. 2007, 40 (5): 199-200. 10.1055/s-2007-985882. doi:10.1055/s-2007-985882View ArticlePubMedGoogle Scholar
- UpToDate V21.1. Mirtazapine: Drug Information. http://www-uptodate-%20com.proxy2.lib.uwo.ca/contents/mirtazapine-drug-%20information?source=search_result&search=mirtazapine&selectedTitle=1%7E49. Accessed on: 5-11-2013
- UpToDate V21.1. Venlafaxine: Drug Information. http://www-uptodate-%20com.proxy2.lib.uwo.ca/contents/venlafaxine-drug-%20information?source=search_result&search=venlafaxine&selectedTitle=1%7E96. Accessed on: 5-11-2013
- UpToDate V21.1. Paroxetine: Drug Information. http://www-uptodate-%20com.proxy2.lib.uwo.ca/contents/paroxetine-drug-%20information?source=search_result&search=paroxetine&selectedTitle=1%7E127. Accessed on 5-11-13
- Paxil [product monograph]: Compendium of Pharmaceuticals and Specialties. 2008, Ottawa, Canada: Canadian Pharmacists Association, 1645-1655.Google Scholar
- Effexor [product monograph]: Compendium of Pharmaceuticals and Specialties. 2008, Ottawa, Canada: Canadian Pharmacists Association, 766-776.Google Scholar
- Remeron [product monograph]: Compendium of Pharmaceuticals and Specialties. 2008, Ottawa, Canada: Canadian Pharmacists Association, 1908-1911.Google Scholar
- Canada S: Population by sex and age group, by province and territory. 2012, Ottawa: Statistics Canada, Available at: http://www.statcan.gc.ca/tables-tableaux/sum-som/l01/cst01/demo31a-eng.htm Google Scholar
- Von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP: The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol. 2008, 61 (4): 344-349. 10.1016/j.jclinepi.2007.11.008. doi:10.1016/j.jclinepi.2007.11.008View ArticlePubMedGoogle Scholar
- Levy AR, O’Brien BJ, Sellors C, Grootendorst P, Willison D: Coding accuracy of administrative drug claims in the Ontario Drug Benefit database. Can J Clin Pharmacol. 2003, 10 (2): 67-71. Available at: http://www.ncbi.nlm.nih.gov/pubmed/12879144 PubMedGoogle Scholar
- Gandhi S, Shariff SZ, Beyea MM, Weir MA, Hands T, Kearns G, Garg AX: Identifying geographical regions serviced by hospitals to assess laboratory-based outcomes. BMJ open. 2013, 3 (1): 1-6. doi:10.1136/bmjopen-2012-001921View ArticleGoogle Scholar
- Zhao YY, Weir MA, Manno M, Cordy P, Gomes T, Hackam DG, Juurlink DN, Mamdani M, Moist L, Parikh CR, Paterson JM, Wald R, Yao Z, Garg AX: New fibrate use and acute renal outcomes in elderly adults: a population- based study. Ann Intern Med. 2012, 156 (8): 560-569. 10.7326/0003-4819-156-8-201204170-00401.View ArticlePubMedGoogle Scholar
- Shih AW, Weir MA, Clemens KK, Yao Z, Gomes T, Mamdani MM, Juurlink DN, Hird A, Hodsman A, Parikh CR, Wald R, Cadarette SM, Garg AX: Oral bisphosphonate use in the elderly is not associated with acute kidney injury. Kidney Int. 2012, 82 (8): 903-908. 10.1038/ki.2012.227.View ArticlePubMedGoogle Scholar
- Lam NN, Weir MA, Yao Z, Blake PG, Beyea MM, Gomes T, Gandhi S, Mamdani M, Wald R, Parikh CR, Hackam DG, Garg AX: Risk of acute kidney injury from oral acyclovir: A population-based study. Am J Kidney Dis. 2013, 61 (5): 723-729. 10.1053/j.ajkd.2012.12.008.View ArticlePubMedGoogle Scholar
- Fleet JL, Dixon SN, Shariff SZ, Quinn RR, Nash DM, Harel Z, Garg AX: Detecting chronic kidney disease in population-based administrative databases using an algorithm of hospital encounter and physician claim codes. BMC Nephrol. 2013, 14: 81-10.1186/1471-2369-14-81.View ArticlePubMedPubMed CentralGoogle Scholar
- Mitsch AL: Antidepressant adverse drug reactions in older adults: Implications for RNs and APNs. Geriatric nursing (New York, NY). 2012, 34 (1): 53-61.View ArticleGoogle Scholar
- Williams J, Young W: A summary of studies on the quality of health care administrative databases in Canada. 1996, Ottawa: Canadian Medical Association, 339-45.Google Scholar
- Jha P, Deboer D, Sykora K, Naylor C: Characteristics and mortality outcomes of thrombolysis trial participants and nonparticipants: a population-based comparison. J Am Coll Cardiol. 1996, 27: 1335-1342. 10.1016/0735-1097(96)00018-6.View ArticlePubMedGoogle Scholar
- Austin P: Using the standardized difference to compare the prevalence of a binary variable between Two groups in observational research. Communication in Statistics - Simulation and Computation. 2009, 38: 1228-1234. 10.1080/03610910902859574.View ArticleGoogle Scholar
- Empana JP, Sykes DH, Luc G, Juhan-Vague I, Arveiller D, Ferrieres J, Amouyel P, Bingham A, Montaye M, Ruidavets JB, Haas B, Evans A, Jouven X, Ducimetiere P, PRIME Study Group: Contributions of depressive mood and circulating inflammatory markers to coronary heart disease in healthy European men: the Prospective Epidemiological Study of Myocardial Infarction (PRIME). Circulation. 2005, 111 (18): 2299-2305. 10.1161/01.CIR.0000164203.54111.AE. doi:10.1161/01.CIR.0000164203.54111.AEView ArticlePubMedGoogle Scholar
- Barefoot JC, Burg MM, Carney RM, Cornell CE, Czajkowski SM, Freedland KE, Hosking JD, Khatri P, Pitula CR, Sheps D: Aspects of social support associated with depression at hospitalization and follow-up assessment among cardiac patients. J Cardpulm Rehabil. 2003, 23 (6): 404-412. 10.1097/00008483-200311000-00002. Available at: http://www.ncbi.nlm.nih.gov/pubmed/14646786 View ArticleGoogle Scholar
- Bonnet F, Irving K, Terra J-L, Nony P, Berthezène F, Moulin P: Anxiety and depression are associated with unhealthy lifestyle in patients at risk of cardiovascular disease. Atherosclerosis. 2005, 178 (2): 339-344. 10.1016/j.atherosclerosis.2004.08.035. doi:10.1016/j.atherosclerosis.2004.08.035View ArticlePubMedGoogle Scholar
- Koo JR, Yoon JW, Kim SG, Lee YK, Oh KH, Kim GH, Kim HJ, Chae DW, Noh JW, Lee SK, Son BK: Association of depression with malnutrition in chronic hemodialysis patients. Am J Kidney Dis. 2003, 41 (5): 1037-1042. 10.1016/S0272-6386(03)00201-4. Available at: http://www.ncbi.nlm.nih.gov/pubmed/12722038 View ArticlePubMedGoogle Scholar
- Ontario Ministry of Finance: Ontario Population Projections 2011–2036: Ontario and Its 49 Census Divisions. 2012, Toronto: Queen’s Printer for Ontario, Ref Type: ReportGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2369/15/79/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.